Amphotericin B therapy continues to be the "gold standard" in the treatment of invasive aspergillosis in the immunocompromised host. Although Aspergillus fumigatus and Aspergillus flavus constitute the major species, several reports have described invasive pulmonary or disseminated disease due to the less common Aspergillus terreus and dismal clinical outcomes with high-dose amphotericin B. We therefore evaluated 101 clinical isolates of A. terreus for their susceptibility to amphotericin B and the investigational triazole voriconazole by using the National Committee for Clinical Laboratory Standards M27-A method modified for mould testing. Forty-eight-hour MICs indicated 98 and 0% resistance to amphotericin B and voriconazole, respectively. We conclude that A. terreus should be added to the list of etiologic agents refractory to conventional amphotericin B therapy and suggest the potential clinical utility of voriconazole in aspergillosis due to this species.
Isolates were evaluated by use of the National Committee for Clinical Laboratory Standards broth macrodilution method M27-A (20) . Briefly, isolates were grown on PFA for 7 to 10 days at 25°C to induce conidial formation. Mature PFA A. terreus slant cultures and the control strain Paecilomyces UTHSC 90-450 were overlaid with sterile distilled water, and suspensions were made by gently scraping the colonies with the tip of a Pasteur pipette. Heavy hyphal fragments were allowed to settle, and the upper, homogeneous conidial suspensions were removed. Conidia were counted with a hemacytometer, and the inoculum was standardized to 1.0 ϫ 10 5 CFU/ml. Conidial suspensions were further diluted 1:10 in medium for a final inoculum concentration of 1.0 ϫ 10 4 CFU/ml. Final drug concentrations were 0.03 to 16 g/ml for amphotericin B (E. R. Squibb & Sons, Princeton, N.J.) and 0.03 or 0.125 to 16 g/ml for voriconazole (Pfizer Inc., New York, N.Y.). Amphotericin B was tested in antibiotic medium 3 (Difco Laboratories, Detroit, Mich.), while voriconazole was tested in RPMI 1640 with L-glutamine and morpholinepropanesulfonic acid (MOPS) buffer at 165 mM and without sodium bicarbonate (American Biorganics, Inc., Niagara Falls, N.Y.). Previously prepared frozen-drug tubes containing 0.1 ml of drug were allowed to thaw and were inoculated with 0.9 ml of the conidial-medium suspension. A drug-free growth control tube was included with each isolate and the control organism. Tubes were incubated at 35°C, and MICs were read at the first 24-h interval when growth was observed in the drug-free control tube. MICs were defined as the first tube with a score of 0 (optically clear) for amphotericin B and a score of 2 (Ն80% reduction in turbidity compared to that in the drugfree control tube) for voriconazole. The minimum lethal concentrations (MLCs) were determined by plating 100 l from the drug-free control tube and each negative tube onto a drugfree Sabouraud dextrose agar plate. The MLC was defined as the lowest concentration of antifungal compound resulting in five or fewer colonies, which corresponded to 0.1% of the control inoculum or a 99.9% reduction (1, 27) . Both MICs and MLCs were evaluated after 48 h of incubation, the time currently being used for Aspergillus species in ongoing studies of filamentous fungi by the National Committee for Clinical Laboratory Standards Subcommittee on Antifungal Susceptibility Testing.
Antifungal susceptibility data were obtained for 101 clinical isolates of A. terreus. As we sought to determine the lethal as well as the static activity of amphotericin B, both MICs and MLCs were determined for this agent. Moreover, prior reports indicating fungicidal activity of voriconazole against Aspergillus species (2) prompted us to test a random subset of isolates for MLCs. The completed study consisted of amphotericin B MIC and MLC data for 101 isolates and voriconazole MIC data for 101 isolates and MLC data for 51 isolates. The geometric means are displayed in Table 1 . For amphotericin B, only 1.98% of the 48-h MICs appeared susceptible (MIC, Յ1 g/ ml), with a mean 48-h MIC of 3.37 g/ml; MLCs were elevated beyond achievable levels, with mean 24-and 48-h concentrations of 7.03 and 13.4 g/ml, respectively. Conversely, 48-h voriconazole MICs were all well within achievable levels, based upon a therapeutic range of 2 to 10 g/ml (23a), with a mean 48-h MIC of 0.22 g/ml; mean MLCs at 24 and 48 h were 5.39 and 17.4 g/ml, respectively. For the control strain, the mean 48-h MIC and MLC were 0.38 and 2 g/ml for amphotericin B and 0.02 and 8 g/ml for voriconazole, respectively. The distribution of MICs and MLCs of both drugs is displayed in Table 2 . The 48-h amphotericin B and voriconazole MICs at which 90% of the isolates were inhibited (MIC 90 s) were 4 and 0.25 g/ml, respectively. The MLC at which 90% of the isolates were killed (MLC 90 ) was 16 g/ml for both drugs.
Despite the empiric use of amphotericin B in systemic, lifethreatening mycoses, several reports have described in vitro tolerance or resistance of Aspergillus species (3, 22, 32, 33) , particularly A. terreus (11, 14) , and in vivo clinical failures for other genera, for which MLCs are elevated (22, 39) . Although numerous factors outlined by Rex et al. (24) contribute to overall clinical efficacy with antifungal drug therapy (pharmacokinetics of the drug, general host factors, site of infection, and virulence of the pathogen), in vitro antifungal susceptibility data suggesting resistance appear useful in predicting clinical response. The survival rate for immunocompromised hosts with invasive pulmonary or disseminated aspergillosis caused by A. terreus is dismal (such infection is frequently fatal), and a review of the literature documents that therapy with amphotericin B frequently fails to eradicate the organism.
The in vitro data generated by this study appear to substantiate the resistance of this species of Aspergillus to amphotericin B. In addition to elevated MICs, MLCs were also elevated beyond levels achievable for the standard formulation of amphotericin B, suggesting a lack of fungicidal activity as well. This finding is significant, as amphotericin B is usually considered fungicidal, but it frequently fails to "kill" organisms when host immune defenses are lacking. The data for voriconazole appear more encouraging with regard to fungistatic properties. Mean 24-and 48-h MICs of 0.12 and 0.22 g/ml, respectively, indicate activity against A. terreus at levels easily achievable with standard dosing regimens of voriconazole (48-h MIC 90 , 0.25 g/ml). Despite previous reports of the in vitro fungicidal activity of voriconazole against Aspergillus species (2, 8, 12) , mean 24-and 48-h MLCs of 5.39 and 17.4 g/ml, respectively, against 51 clinical isolates of A. terreus failed to support these data (MLC 90 , 16 g/ml), as values were beyond achievable levels. This result may be due in part to a lack of a consensus for the definition of MLC for antifungal testing. Our method requires a 99.9% kill rate, while other investigators defined their MLC methods as having kill rates as low as 95%. This less stringent definition would produce MLCs lower than those that we reported. In conclusion, our data appear to confirm that A. terreus demonstrates in vitro resistance to amphotericin B. Voriconazole has consistently low MICs, while MLCs remain high. Further animal studies and prospective in vitro-in vivo correlations are warranted. 
